BCAX (Bicara Therapeutics Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by BCAX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-10 | Ryan Cohlhepp | President, COO & Interim CEO | MIXED | — | — |
| 2026-08-14 | Jennifer Larson | Chief Financial Officer | A | — | — |
| 2026-08-12 | Claire Mazumdar | Chief Executive Officer | MIXED | — | — |
| 2026-08-12 | Ivan Hyep | Chief Financial Officer | MIXED | — | — |
| 2026-08-12 | Ryan Cohlhepp | President and COO | MIXED | — | — |
| 2026-07-29 | Jeremy Bender | Director | A | — | — |
| 2026-07-29 | Christy J. Oliger | Director | A | — | — |
| 2026-07-14 | Claire Mazumdar | Chief Executive Officer | MIXED | — | — |
| 2026-07-10 | Ryan Cohlhepp | President and COO | MIXED | — | — |
| 2026-07-10 | Ivan Hyep | Chief Financial Officer | MIXED | — | — |
| 2026-06-10 | Kiran Mazumdar-Shaw | Director | A | — | — |
| 2026-06-10 | Christopher Bowden | Director | A | — | — |
| 2026-06-10 | RA CAPITAL MANAGEMENT, L.P. | Director | A | — | — |
| 2026-06-10 | Kate Haviland | Director | A | — | — |
| 2026-06-10 | MICHAEL POWELL | Director | A | — | — |
| 2026-06-10 | Scott M. Robertson | Director | A | — | — |
| 2026-06-10 | Jake Simson | Director | A | — | — |
| 2026-05-26 | Ivan Hyep | Chief Financial Officer | MIXED | — | — |
| 2026-05-20 | Claire Mazumdar | Chief Executive Officer | MIXED | — | — |
| 2026-05-18 | Ryan Cohlhepp | President and COO | MIXED | — | — |
| 2026-05-12 | William Schelman | Chief Medical Officer | A | — | — |
| 2026-04-28 | David Raben | Chief Medical Officer | MIXED | — | — |
| 2026-04-22 | Ivan Hyep | Chief Financial Officer | MIXED | — | — |
| 2026-04-20 | Claire Mazumdar | Chief Executive Officer | MIXED | — | — |
| 2026-04-17 | Ryan Cohlhepp | President and COO | MIXED | — | — |
| 2026-03-26 | David Raben | Chief Medical Officer | MIXED | — | — |
| 2026-03-24 | Ivan Hyep | Chief Financial Officer | MIXED | — | — |
| 2026-03-20 | Claire Mazumdar | Chief Executive Officer | MIXED | — | — |
| 2026-03-17 | Ryan Cohlhepp | President and COO | MIXED | — | — |
| 2026-03-11 | Claire Mazumdar | Chief Executive Officer | MIXED | — | — |
| 2026-03-06 | Claire Mazumdar | Chief Executive Officer | MIXED | — | — |
| 2026-03-05 | Ivan Hyep | Chief Financial Officer | MIXED | — | — |
| 2026-03-05 | Ryan Cohlhepp | President and COO | MIXED | — | — |
| 2026-03-05 | David Raben | Chief Medical Officer | MIXED | — | — |
| 2026-03-02 | RA Capital Healthcare Fund LP | Director | Buy | — | — |
| 2026-02-27 | Ryan Cohlhepp | President and COO | MIXED | — | — |
| 2026-02-04 | Ivan Hyep | Chief Financial Officer | A | — | — |
| 2026-02-04 | David Raben | Chief Medical Officer | A | — | — |
| 2026-02-04 | Claire Mazumdar | Chief Executive Officer | A | — | — |
| 2026-02-04 | Ryan Cohlhepp | President and COO | A | — | — |
| 2026-02-04 | Lara Meisner | Chief Legal Officer | A | — | — |
| 2026-01-26 | Ryan Cohlhepp | President and COO | Sell | — | — |
| 2026-01-26 | Ivan Hyep | Chief Financial Officer | MIXED | — | — |
| 2026-01-20 | Ryan Cohlhepp | President and COO | Sell | — | — |
| 2025-12-29 | Ryan Cohlhepp | President and COO | M | — | — |
| 2025-12-29 | David Raben | Chief Medical Officer | M | — | — |
| 2025-12-23 | Ivan Hyep | Chief Financial Officer | MIXED | — | — |
| 2025-12-18 | Claire Mazumdar | Chief Executive Officer | M | — | — |
| 2025-12-16 | Ryan Cohlhepp | President and COO | MIXED | — | — |
| 2025-11-25 | Ivan Hyep | Chief Financial Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 4,603,418 | — |
| — | 10%+ Owner | 4,443,122 | — |
| — | Director | 2,652,575 | — |
| — | — | 1,960,425 | — |
| — | — | 1,013,853 | — |
| — | 10%+ Owner | 897,587 | — |
| — | Chief Executive Officer | 362,152 | — |
| — | Director | 324,552 | — |
| — | President, COO & Interim CEO | 181,641 | — |
| — | Chief Financial Officer | 129,855 | — |
| — | Chief Medical Officer | 55,286 | — |
| — | — | 10,818 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BCAX quote page; the site-wide leaderboard is on the insider transactions hub.